What's Happening?
The Dog Aging Project, co-founded by biologist Matt Kaeberlein, is studying over 50,000 dogs to understand aging processes that could benefit human longevity. The project collects data on dogs' diets, exercise, and conducts MRIs of their brains. Dogs,
like humans, suffer from aging-related diseases, and their faster aging process allows scientists to gather data more quickly than with human subjects. The project aims to bridge the gap between mouse and human trials, as dogs share environments and lifestyles with humans. Neuropathologist Dr. Dirk Keene, motivated by personal experiences with Alzheimer's, is involved in examining canine brains post-mortem to draw parallels with human dementia.
Why It's Important?
The research could significantly impact the understanding of aging and dementia in humans. By studying dogs, researchers hope to identify treatments that could slow cognitive decline and extend life expectancy. The project has already influenced over 50 scientific studies, highlighting correlations between lifestyle, environment, and disease risk. The potential to apply findings from canine studies to human health could lead to breakthroughs in treating age-related diseases, offering hope for improved quality of life and longevity.
What's Next?
The Dog Aging Project is conducting a larger clinical trial, funded partly by the National Institutes of Health, to test the drug rapamycin on dogs. This trial aims to determine if the drug can extend life and improve cognitive function. Additionally, biotech startup Loyal is testing drugs to extend dogs' lifespans, with hopes of applying successful treatments to human aging. The outcomes of these trials could pave the way for new longevity treatments in humans, contingent on further research and regulatory approvals.
